Login / Signup

Targeted degradation via direct 26S proteasome recruitment.

Charlene BashoreSumit PrakashMatthew C JohnsonRyan J ConradIvy A KekessieSuzie J ScalesNoriko IshisokoTracy KleinheinzPeter S LiuNataliya PopovychAaron T WeckslerLijuan ZhouChristine TamInna ZilberleybRajini SrinivasanRobert A BlakeAimin SongSteven T StabenYingnan ZhangDavid ArnottWayne J FairbrotherScott A FosterIngrid E WertzClaudio CiferriErin C Dueber
Published in: Nature chemical biology (2022)
Engineered destruction of target proteins by recruitment to the cell's degradation machinery has emerged as a promising strategy in drug discovery. The majority of molecules that facilitate targeted degradation do so via a select number of ubiquitin ligases, restricting this therapeutic approach to tissue types that express the requisite ligase. Here, we describe a new strategy of targeted protein degradation through direct substrate recruitment to the 26S proteasome. The proteolytic complex is essential and abundantly expressed in all cells; however, proteasomal ligands remain scarce. We identify potent peptidic macrocycles that bind directly to the 26S proteasome subunit PSMD2, with a 2.5-Å-resolution cryo-electron microscopy complex structure revealing a binding site near the 26S pore. Conjugation of this macrocycle to a potent BRD4 ligand enabled generation of chimeric molecules that effectively degrade BRD4 in cells, thus demonstrating that degradation via direct proteasomal recruitment is a viable strategy for targeted protein degradation.
Keyphrases
  • induced apoptosis
  • cancer therapy
  • electron microscopy
  • drug discovery
  • cell cycle arrest
  • cell therapy
  • small molecule
  • high resolution
  • protein protein
  • single molecule
  • pi k akt